Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:FCSC
- CUSIP: N/A
- Web: www.fibrocell.com
Capitalization:- Market Cap: $54.01 million
- Outstanding Shares: 14,717,000
Average Prices:- 50 Day Moving Avg: $2.94
- 200 Day Moving Avg: $2.67
- 52 Week Range: $1.57 - $4.64
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.04
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $252,000.00
- Price / Sales: 200.90
- Book Value: ($0.75) per share
- Price / Book: -4.59
Profitability:- EBIDTA: ($18,040,000.00)
- Net Margins: -4,307.60%
- Return on Equity: -293.07%
- Return on Assets: -91.03%
Debt:- Current Ratio: 4.78%
- Quick Ratio: 4.78%
Misc:- Average Volume: 79,250 shs.
- Beta: 0.31
- Short Ratio: 3.46
Frequently Asked Questions for Fibrocell Science (NASDAQ:FCSC)
What is Fibrocell Science's stock symbol?
Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."
How were Fibrocell Science's earnings last quarter?
Fibrocell Science Inc (NASDAQ:FCSC) announced its earnings results on Wednesday, August, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. View Fibrocell Science's Earnings History.
When will Fibrocell Science make its next earnings announcement?
Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2017?
3 equities research analysts have issued 1-year price objectives for Fibrocell Science's stock. Their forecasts range from $2.00 to $7.00. On average, they anticipate Fibrocell Science's stock price to reach $4.90 in the next twelve months. View Analyst Ratings for Fibrocell Science.
Who are some of Fibrocell Science's key competitors?
Some companies that are related to Fibrocell Science include Palatin Technologies (PTN), aTyr Pharma (LIFE), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR), Zynerba Pharmaceuticals (ZYNE), ArQule (ARQL), Vernalis plc (VER), Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Galectin Therapeutics (GALT), Navidea Biopharmaceuticals (NAVB), Infinity Pharmaceuticals (INFI), ReNeuron Group Plc (RENE), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS) and Abzena PLC (ABZA).
Who are Fibrocell Science's key executives?
Fibrocell Science's management team includes the folowing people:
- Douglas J. Swirsky, Chairman of the Board
- John M. Maslowski, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer
- Lisa A. Embon, Vice President - of Corporate Accounting , Controller
- Kelvin Moore, Lead Independent Director
- Julian P. Kirk, Director
- Marcus E. Smith, Director
- Marc B. Mazur, Independent Director
- Christine Thompson St.Clare, Independent Director
Who owns Fibrocell Science stock?
Fibrocell Science's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Third Security LLC (37.70%), FMR LLC (5.79%), Vanguard Group Inc. (2.36%), Cambridge Investment Research Advisors Inc. (0.46%), Creative Planning (0.42%) and Parametric Portfolio Associates LLC (0.33%). View Institutional Ownership Trends for Fibrocell Science.
Who sold Fibrocell Science stock? Who is selling Fibrocell Science stock?
Who bought Fibrocell Science stock? Who is buying Fibrocell Science stock?
How do I buy Fibrocell Science stock?
Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fibrocell Science's stock price today?
One share of Fibrocell Science stock can currently be purchased for approximately $3.44.
MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Fibrocell Science (NASDAQ:FCSC)Earnings History by Quarter for Fibrocell Science (NASDAQ FCSC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | | | | | | | |
| 8/9/2017 | Q2 2017 | ($0.31) | ($0.31) | | | View | Listen |  |
| 5/10/2017 | Q1 2017 | ($0.29) | ($0.58) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.15) | ($0.05) | $0.07 million | $0.22 million | View | N/A | |
| 3/10/2016 | Q415 | ($0.17) | ($0.40) | $0.07 million | $0.08 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.07) | $0.06 million | $0.08 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.16) | ($0.17) | $0.09 million | $0.14 million | View | N/A | |
| 5/8/2015 | Q1 2015 | ($0.16) | ($0.17) | $0.05 million | $0.19 million | View | N/A | |
| 3/13/2015 | Q4 2014 | ($0.16) | ($0.16) | $0.06 million | $0.06 million | View | N/A | |
| 11/7/2014 | Q3 14 | ($0.14) | ($0.17) | $0.06 million | $0.02 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.18) | ($0.08) | $0.07 million | $0.06 million | View | N/A | |
| 5/19/2014 | Q114 | ($0.15) | ($0.35) | $0.05 million | $0.05 million | View | N/A | |
| 3/17/2014 | Q414 | ($0.26) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($1.01)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.31) | ($0.07) | ($0.19) |
| Q2 2017 | 4 | ($0.34) | ($0.07) | ($0.20) |
| Q3 2017 | 4 | ($0.35) | ($0.05) | ($0.20) |
| Q4 2017 | 3 | ($0.37) | ($0.05) | ($0.20) |
| Q1 2018 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q2 2018 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q3 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
(Data provided by Zacks Investment Research)
Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Fibrocell Science (NASDAQ:FCSC)Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 54.70%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/2/2016 | David Pernock | Chairman | Buy | 50,000 | $0.92 | $46,000.00 | |
| 11/13/2015 | David Pernock | CEO | Buy | 3,000 | $5.00 | $15,000.00 | |
| 8/11/2015 | David Pernock | CEO | Buy | 3,500 | $6.54 | $22,890.00 | |
| 7/27/2015 | Randal J Kirk | Major Shareholder | Buy | 975,987 | $5.80 | $5,660,724.60 | |
| 5/13/2015 | David Pernock | CEO | Buy | 16,600 | $4.30 | $71,380.00 | |
| 12/12/2014 | David Pernock | CEO | Buy | 5,000 | $2.52 | $12,600.00 | |
| 11/20/2014 | David Pernock | CEO | Buy | 5,000 | $2.54 | $12,700.00 | |
| 11/20/2014 | John Michael Maslowski | VP | Buy | 1,000 | $2.54 | $2,540.00 | |
| 6/5/2014 | Christine St.Clare | Director | Buy | 10,000 | $3.00 | $30,000.00 | |
| 6/5/2014 | David Pernock | CEO | Buy | 12,500 | $2.95 | $36,875.00 | |
| 6/4/2014 | Kelvin Moore | Director | Buy | 4,557 | $2.99 | $13,625.43 | |
| 6/4/2014 | Randal J Kirk | Major Shareholder | Buy | 400,000 | $2.90 | $1,160,000.00 | |
| 1/24/2014 | Randal J Kirk | Major Shareholder | Buy | 1,024,590 | $4.88 | $4,999,999.20 | |
| 11/21/2013 | David Pernock | CEO | Buy | 10,000 | $3.69 | $36,900.00 | |
| 11/20/2013 | Gregory L Weaver | CFO | Buy | 10,000 | $3.51 | $35,100.00 | |
| 10/1/2013 | Randal J Kirk | Major Shareholder | Buy | 3,658,536 | $4.10 | $14,999,997.60 | |
| 7/26/2013 | Randal J Kirk | Major Shareholder | Buy | 1,243,781 | $6.03 | $7,499,999.43 | |
(Data available from 1/1/2013 forward)
Headline Trends for Fibrocell Science (NASDAQ:FCSC)
Latest Headlines for Fibrocell Science (NASDAQ:FCSC)
| Source: |
|
Fibrocell Science (FCSC) Chart for Saturday, September, 23, 2017
